ChondroGene Inc. Receives Conditional Approval To Trade On The Toronto Stock Exchange

Published: Sep 22, 2006

TORONTO, Sept. 22 /PRNewswire-FirstCall/ - ChondroGene Limited announced today that it has received conditional approval to list its common shares on the Toronto Stock Exchange (TSX) subject to filing of final documentation. It is expected that the Company's common shares will commence trading on the TSX by October 31, 2006. Contemporaneous with the listing on the TSX, the Company will change its name to GeneNews Limited and will trade under the symbol GEN. The Company received shareholder approval to change its name at the last Annual Meeting held on June 12, 2006. In conjunction with its move to the TSX, ChondroGene common shares will be de-listed from and cease trading on the TSX Venture Exchange.

"Listing on the TSX is a significant achievement for our Company and a natural progression in our growth," stated Dr. K. Wayne Marshall, MD, PhD, President and CEO of ChondroGene. "At the same time we will be changing our name to GeneNews Limited since we have broadened our focus beyond osteoarthritis and have applied our Sentinel Principle technology to many disease areas. GeneNews more accurately reflects the business of the company in taking a genomics approach to the study of all disease and the development of disease-specific tests such as ColonSentry(TM), our first commercial product."

About ChondroGene


ChondroGene is focussed on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. ChondroGene is currently applying the Sentinel Principle in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. ChondroGene's first product in development, ColonSentry(TM), is a blood-based test that can detect colon cancer and pre-cancerous polyps. For more information on ChondroGene, visit

The TSX Venture Exchange has not reviewed and does not accept

responsibility for the adequacy or accuracy of this news release.

ChondroGene Limited

CONTACT: Dr. K. Wayne Marshall, President & CEO, (416) 650-0060 x234,; Bruno Maruzzo, Corporate Development, (416)650-0060 x237,

Back to news